Related Experiment Video

Updated: Aug 29, 2026

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Biosafety of onco-retroviral vectors

Thierry VandenDriessche1, Désiré Collen, Marinee K L Chuah

  • 1Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology-University of Leuven, 49 Herestraat, B-3000 Leuven, Belgium.

Current Gene Therapy
|December 20, 2003
PubMed

Insights

Oncoretroviral vectors are generally safe for gene therapy, but carry a risk of cancer due to gene insertion. New strategies are needed to improve safety and accurately assess risks.

Area of Science:

  • Gene Therapy
  • Retroviral Vectors
  • Oncology

Background:

  • Oncoretroviral vectors have demonstrated relative safety in extensive gene therapy trials.
  • Previous concerns about replication-competent retroviruses (RCR) have been mitigated through improved vector design.

Purpose of the Study:

  • To evaluate the safety of oncoretroviral vectors in gene therapy.
  • To identify and address the risks associated with oncoretroviral vector integration.

Main Methods:

  • Review of preclinical studies and clinical trial data involving oncoretroviral vectors.
  • Analysis of oncogene activation and lymphomagenesis associated with vector insertion.
  • Assessment of germline transmission and horizontal transmission risks.

Main Results:

  • While generally safe, oncoretroviral vectors pose a risk of malignant transformation via insertional oncogene activation.
  • Recent studies indicate lymphomagenesis risk even with RCR-free vectors.
  • Germline and horizontal transmission risks are considered low.

Conclusions:

  • Further safety enhancements, including suicide genes and chromosomal insulators, are warranted for oncoretroviral vectors.
  • Long-term clinical follow-up and insertion site analysis are crucial for accurate risk assessment.

More Related Videos

Transduction of Human Cells with Polymer-complexed Ecotropic Lentivirus for Enhanced Biosafety14:03

Transduction of Human Cells with Polymer-complexed Ecotropic Lentivirus for Enhanced Biosafety

Published on: July 24, 2011

A Tetracycline-regulated Cell Line Produces High-titer Lentiviral Vectors that Specifically Target Dendritic Cells16:04

A Tetracycline-regulated Cell Line Produces High-titer Lentiviral Vectors that Specifically Target Dendritic Cells

Published on: June 19, 2013

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...